Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population.
Sachin DavidSukesh C NairG Surender SinghAnsu Abu AlexSaravanan GanesanHamenth Kumar PalaniNithya BalasundaramKavitha M LakshmiAditi JoshiS KannanAnu KorulaFouzia Nambiatheyil AboobackerAby AbrahamBiju GeorgeShashikant Janardan ApteAlok SrivastavaVikram MathewsPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)
The overall prevalence of inhibitors in patients with severe haemophilia A is similar to that reported among patients receiving regular replacement therapy. The data from this study, limited by its retrospective and cross-sectional study design, would suggest that genetic rather than environmental are more likely to impact the development of inhibitors.
Keyphrases
- replacement therapy
- cross sectional
- end stage renal disease
- risk factors
- newly diagnosed
- ejection fraction
- chronic kidney disease
- early onset
- genome wide
- smoking cessation
- copy number
- prognostic factors
- electronic health record
- gene expression
- combination therapy
- dna methylation
- risk assessment
- human health
- life cycle
- data analysis